REG - IXICO plc - Notice of Capital Markets Day

IXICOAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250930:nRSd2865Ba&default-theme=true

RNS Number : 2865B  IXICO plc  30 September 2025

IXICO plc

("IXICO", the "Company" or the "Group")

 

Notice of Capital Markets Day

 

 

30 September 2025 IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader
in neuroscience imaging and biomarker analytics, using its AI-driven platform
to help advance drug development in neurological disorders, today announces it
will be hosting a Capital Markets Day for analysts and institutional investors
between 14:00 - 17:00 GMT on 30 October 2025 at the offices of Cavendish
Capital Markets.

 

The event will provide the opportunity to hear from IXICO's CEO and
strengthened senior management team, key customers and industry opinion
leaders. The agenda will explore the Company's growth strategy and future
direction, the neuroscience landscape trends and expansion opportunities for
the Company, IXICO's technology roadmap and a detailed explanation of IXICO's
AI-driven precision medicine technology platform

 

Existing and prospective retail investors are welcome to join via a live
webcast. The facility to submit questions will be available on this platform.

 

To register your interest please contact Cavendish Capital Markets on +44 (0)
20 7220 0500 or via email ir@cavendish.com (mailto:ir@cavendish.com)

 

To register for the live webcast investors can sign up to Investor Meet
Company for free and add to meet IXICO PLC via:
https://www.investormeetcompany.com/ixico-plc/register-investor
(https://www.investormeetcompany.com/ixico-plc/register-investor)

 

 

Ends

 

For further information please contact:

 IXICO plc                                         +44 (0) 20 3763 7499
 Grant Nash, Chief Financial Officer

 James Chandler, Chief Business Officer

 Cavendish Capital Markets Limited                 +44 (0) 20 7220 0500

 (Nominated Adviser and Sole Broker)
 Giles Balleny / Isaac Hooper (Corporate Finance)

 Nigel Birks (Healthcare Specialist Sales)

 Harriet Ward (Corporate Broking)

 Michael F Johnson (Sales)

 

 

About IXICO www.IXICO.com (http://www.IXICO.com)

IXICO is a global leader in neuroscience imaging and biomarker analytics,
using its proprietary AI-driven platform to help advance the treatment of
neurological disorders and reduce the uncertainties associated with drug
discovery, development and monitoring.   As a key part of the global
neurological disease research community, the Company has built a global
reputation and 20-year track record as an end-to-end Imaging Contract Research
Organisation (iCRO) working with leading pharma companies, innovative
biotech's, disease consortia and non-profit organisations. IXICO has supported
hundreds of neurological clinical trials, analysed hundreds of thousands scans
and built an expansive network of expert imaging centres around the world.

 

The IXICO Platform is tailor-made for neurological disease, reliably
processing data from global trials, precisely measuring key imaging biomarkers
associated with the identification, progression and treatment of diseases such
as Alzheimer's, Huntington's and Parkinson's.  Image data is interrogated by
the Platform and IXICO's expert scientists translating complex data into
clinically meaningful while minimizing data variability and increasing
reproducibility.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPPUCPBUPAGQB